AI and digital health are no longer side stories. They are changing how life sciences companies build, launch, sell, and scale.
This section tracks the technologies and the operating-model consequences that matter.
Digital health companies love to talk about defensible technology. European health systems are much less romantic. They care whether the product gets used, fits the workflow, generates evidence, survives procurement and justifies reimbursement after the first enthusiasm fades. In Europe, a CE mark, a DiGA listing, a PECAN decision or a positive early value signal…
The EU AI Act has given pharma, MedTech and digital health companies more time on the most resource-intensive part of the regime. It has not given commercial teams permission to wait. On 29 June 2026, the Council of the European Union gave final approval to the Digital Omnibus on AI. The package moves the high-risk…
Health Tech Pathways and the Bottleneck Upstream of EU MDR Health Tech Hub Copenhagen has launched an AI-guided platform to help startups navigate MDR. Useful. But the more interesting lesson is what the tool cannot solve: founders who have not yet decided what product they are actually regulating. Health Tech Pathways; HTH Copenhagen. The most…
AI in Commercial Operations AI-Powered Commercial Operating Models in Life Sciences: What Actually Changes Beyond the Hype Every large pharma and MedTech company now has an AI commercial programme. Very few have a new commercial operating model. That gap is the whole story. Who Should Read It? Walk into any large life sciences commercial organisation…
Every health AI model is a decision engine — and an attack surface. The Risks (with Evidence) Why Healthcare Is Special Framework for Defence Aligned with the EU AI Act’s high-risk obligations: risk management, logging, human oversight (European Commission). In healthcare, AI isn’t “just software” — it’s safety-critical infrastructure.
The Promise Pharma spends billions on R&D only to see 90% of drug candidates fail in trials. At the heart of the problem: chemistry is a quantum system, but we’ve been simulating it with classical approximations. Quantum computing, in principle, can simulate molecules and protein folding with physics-native precision, potentially cutting years and billions from discovery…
Quantum computing is the latest shiny object in healthcare IT. Headlines trumpet its ability to solve the unsolvable, to accelerate drug discovery, and to personalise medicine at a level classical AI can only dream of. The reality, however, is a little noisier, literally. In 2025, we are firmly in what researchers call the NISQ era….
What is Artificial Intelligence (AI) in a pharma marketing context? In a pharma commercial context, AI primarily refers to generative AI, which differs from traditional “classical AI” or machine learning. AI in Commercial Operations Agentic AI in Life Sciences Commercial: What Actually Changes in Your Operating Model Understanding AI in pharma marketing can significantly enhance…
Cancer detection has seen a revolutionary transformation, thanks to the emergence of a technique known as Protein Biomarker Analysis using Proximity Ligation Assays (PLA). This novel approach is a game changer in identifying cancer at its nascent stages, improving the chances of successful treatment and recovery. But what exactly is PLA, and how does it…
Digital health in 2023 continues to advance rapidly. Medical devices that utilize digital technology are becoming increasingly popular and offer a wide range of benefits, including improved accuracy, increased convenience, and greater efficiency. In this post, we’ll take a look at the top 10 medical devices revolutionizing digital health in 2023. Smart Inhalers Smart inhalers…